Polydex Pharmaceuticals Limited (USA) 

(Public, OTC:POLXF)   Watch this stock   
Find more results for NASDAQ:POLXF

Key stats and ratios

Q3 (Jul '09) 2009
Net profit margin -40.79% -32.99%
Operating margin -40.79% -33.97%
EBITD margin - -23.73%
Return on average assets -28.66% -19.78%
Return on average equity -40.76% -25.52%
Employees 20 -

Address

421 Comstock Road
Toronto, ON M1L 2H5
Canada
+1-416-7552231 (Phone)
+1-416-7550334 (Fax)

Website links

Polydex Pharmaceuticals Limited (USA) discussions

  View all discussions »

Description

Polydex Pharmaceuticals Limited is engaged in the research, development, manufacture and marketing of biotechnology-based products for the human pharmaceutical market, and also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. The Company focuses on the manufacture and sale of Dextran and derivative products, including Iron Dextran and Dextran Sulphate, and other specialty chemicals. The Company conducts its business operations through its two wholly owned subsidiaries: Dextran Products Limited (Dextran Products) and Chemdex Inc (Chemdex).

Officers and directors

George G. Usher
Chairman of the Board, President, Chief Executive Officer
Age: 50
John Alfred Luce
Chief Financial Officer
Age: 62
Sharon L. Wardlaw
Chief Operating Officer, Treasurer, Secretary
Age: 56
Derek John Michael Lederer C.A.
Independent Director
Age: 67
Joseph Buchman
Independent Director
Age: 69
John L.E. Seidler
Independent Director
Age: 73